Charles River Laboratories Inte Price Today
Charles River Laboratories Inte
CRL
Healthcare
$10.59B
💰
Market Cap
21.3
💸
Price to Earnings
$9.7
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
9 |
Strong Buy |
7 |
Hold |
4 |
Sell |
0 |
Strong Sell |
0 |
CRL Price Forecast Target
206.9 👉 280.0 +35%
CRL EPS Forecast
9.7 👉 12.0 +23%
Financials
Profit Margin
12 %
Revenue Growth
12.6 %
Dividend
$ 0
Held Percent
1.0% - Insiders
101.8% - Institutions
-2.8% - Public
Major Fund Holders
-
💰 Vanguard Group Inc $1.2B
-
💰 Blackrock Inc. $990.4M
-
💰 Price (T.Rowe) Associates Inc $518.6M
-
💰 State Street Corporation $424.8M
-
💰 Kayne Anderson Rudnick Investment Management LLC $336.9M
Stock Ideas
Jim Simons Portfolio
Jim Simons, the mastermind behind the Medallion Fund, has achieved such extraordinary returns that he has skyrocketed to the ranks of the world's wealthiest individuals. The secret to his success lies in the fund's implementation of high-frequency t…
David Shaw Portfolio
David Shaw is a renowned computer scientist, technological pioneer, and founder of D.E. Shaw Group, one of the earliest quantitative hedge funds. Shaw pioneered the use of algorithmic and computational modeling in institutional investing. While litt…
Bill Gates Portfolio
With a portfolio valued at over $18 billion, the Bill & Melinda Gates Foundation Trust holds the endowment and funds the Bill & Melinda Gates Foundation. Bill and Melinda are the trustees for the Foundation Trust, and the endowment is managed by a t…
Seth Klarman Portfolio
Seth Klarman's investment prowess is exemplified by his exceptional track record. Since the inception of his fund until 2008, he achieved an impressive compound return-on-investment of 20%. This remarkable achievement showcases his astute investment…📮FAQ
Some Frequently Asked Questions.
The Charles River Laboratories Inte industry is Diagnostics & Research
The Charles River Laboratories Inte sector is Healthcare
The Charles River Laboratories Inte forecasted predicted Price to Earnings PE ratio is 17.3
The Charles River Laboratories Inte Price to Earnings PE ratio is 21.3
The Market Capitalization of Charles River Laboratories Inte is $10.59B
There are total of 50612761 float shares with 101.8% held by Institutions and 1.0% held by insiders
The MCharles River Laboratories Inte forecasted Earnings per Share EPS is $12.0
The Charles River Laboratories Inte Earnings per Share EPS is 9.7
The Charles River Laboratories Inte company has $1462651000 gross profits with 12 profit margins
The Charles River Laboratories Inte Earnings Growth is 0.11% with 0.109% quarterly earnings growth
The Charles River Laboratories Inte Revenue is $4091504128 with 0.126 revenue growth
The price target for Charles River Laboratories Inte stock is $280.0 for the high target and $205.0 for the low target
The consensus analyst recommendations for Charles River Laboratories Inte is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Charles River Laboratories Inte is Buy, with the following breakdown:
- Buy: 9
- Strong Buy: 7
- Hold: 4
- Sell: 0
- Strong Sell: 0
The Beta of Charles River Laboratories Inte is 1.3
The dividend of Charles River Laboratories Inte is $0
The dividend yield of Charles River Laboratories Inte is 0%
The biggest institutional and mutual fund holders of Charles River Laboratories Inte stock are
- Vanguard Group Inc
- Blackrock Inc.
- Price (T.Rowe) Associates Inc
- State Street Corporation
The Charles River Laboratories Inte ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0